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Diabetic neuropathy is one of the most frequent and troublesome complications of diabetes. Although
there has been a continuous increase in the incidence of diabetic neuropathy, treatments have yet to be
found that effectively treat diabetic neuropathy. Neurotrophic factors are proteins that promote the
survival of specific neuronal populations. They also play key roles in the regeneration of peripheral
nervous system. Recent evidence from diabetic animal models and human diabetic subjects suggest that
reduced availability of neurotrophic factors may contribute to the pathogenesis of diabetic neuropathy.
One way to reverse this effect is to take advantage of the finding that bone marrow derived mesenchymal
stem cells (BM-MSCs) promote peripheral nerve repair and the functioning of neurotrophic factors.
Therefore, we speculated that treatment with BM-MSCs could be a viable therapeutic strategy for diabetic
neuropathy. The present study was designed to examine the possible beneficial effect of BM-MSCs on
functions of neurotrophic factors in diabetic neuropathy. To assess this possibility, we used an in vivo
streptozotocin-induced diabetic neuropathy mouse model. Quantitative real-time polymerase-chain
reacion showed that BM-MSCs significantly increase expression levels of neurotrophic factors. Also, BM-
MSCs ameliorated nerve conduction velocity in streptozotocin-treated mice. These results may help to
elucidate the mechanism by which BM-MSCs function as a cell therapy agent in diabetic neuropathy.
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Diabetic neuropathy (DN) is the most common complication
in diabetic patients. DN may not only cause various problems
in daily life, but also, it may affect their prognosis [1,2]. Diabetic
patients suffer from various symptoms of DN such as
spontaneous pain, hyperalgesia and diminished sensation. DN
is the major reason for loss of protective limb mechanical
sensation, traumatic ulceration injures and, therefore,
amputations [3]. A number of mechanisms have been
proposed to link chronic hyperglycemia to diabetes-induced
deficits in motor and sensory nerve conduction velocities and
small fiber sensory neuropathy [4]. Although there has been
a continuous increase in the incidence of DN, current
treatments have yet to effectively treat DN.
The neurotrophin family of neurotrophic factors (NTFs) is
a family of structurally and functionally related peptides that
mediate potent survival and differentiation effects on a wide
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variety of neuronal populations in the nervous systems [5].
But only a few members of the family have particular
importance with regard to the peripheral nervous system (PNS).
Members of this family include brain-derived neurotrophic
factor (BDNF), nerve growth factor (NGF) and neurotrophin-
3 (NT-3). These factors may stimulate nerve regeneration or
collateral sprouting, as well as enhance the normal physiological
functions of surviving neurons. NTFs including NGF and NT-
3 are trophic for specific neuronal populations in the PNS.
This specificity is determined by the receptors expressed by
each neuronal population [6]. NTFs function by binding to
2 classes of receptors: tyrosine kinase receptors (Trk) and p75
receptors [7]. The p75 receptor binds all NTFs with similar
affinity, but with different kinetics [8]. In contrast, the Trk
receptors are more specific. Trk A is expressed on small-
fiber sensory and sympathetic neurons and mediates most
of the biological effects of NGF [9]. Trk C is the receptor
for NT-3 [10]. Also, previous studies have demonstrated that
neurotrophins are key mediators of the myelination program
in the PNS [11-13]. Disturbed axonal growth in diabetes has
been ascribed in part to the reduction of NTFs such as NGF
and NT-3 in peripheral nerves and circumambient muscles
and to decreased expression of their receptors in dorsal root
ganglion cells [14-16].
Diabetes induced neurotrophic dysfunction may contribute
to the pathogenesis of DN. We speculated that bone marrow-
derived mesenchymal stem cells (BM-MSCs) could be a viable
therapeutic strategy for DN because BM-MSCs have been
reported to promote axonal regeneration and functional
recovery of NTFs in peripheral nerve repair [17-19]. Also,
transplantation of BM-MSCs might modulate neurotrophic
functions in streptozotocin (STZ)-treated DN mice. Therefore,
we injected BM-MSCs into the hind limb muscles of DN
mice. Interestingly, this therapy increased expression levels
of NTFs and ameliorated nerve conduction deficits in DN mice.
Materials and Methods
Animals and induction of diabetes
Six-week-old male BALB/c mice were allowed to adapt
to the experimental animal facility for 2 weeks. At 8 weeks
of age they were treated with STZ (Sigma-Aldrich, St. Louis,
MO, USA) to induce diabetes. After anesthesia with a
combination of 100 mg/kg ketamine and 10 mg/kg xylazine,
mice were injected with 60 mg/kg STZ in 50 mM sodium
citrate buffer, pH 4.5, daily for 5 days [20]. Control mice
were treated with daily injections of citrate buffer. One week
after the last injection, using a glucometer, serum glucose
was measured in blood samples taken from mouse tail veins.
Mice with plasma glucose concentrations of at least 250 mg/
dL were selected as the STZ-induced diabetes group. Mice
were housed in a room maintained under controlled
temperature and humidity on a 12 hour/12 hour light/dark
cycle. All procedures were done in accordance with an animal
protocol approved by the Kyungpook National University
Institutional Animal Care and Use Committee (IACUC).
Isolation and culture of BM-MSCs
Tibias and femurs were dissected from 4- to 6-week-old
BALB/c mice. Bone marrow was harvested, and single-cell
suspensions were obtained using a 40-µm cell strainer
(Becton-Dickinson and Company, Franklin Lakes, NJ, USA).
Approximately 10
6 cells were plated in 25-cm
2 flasks containing
(i) MesenCult
TM MSC Basal Medium, (ii) Mesenchymal Stem
Cell Stimulatory Supplements (Stem Cell Technologies,
Vancouver, BC, Canada) and (iii) antibiotics as in our previous
report [21]. The cell cultures were grown for 1 week, and
the population that was adherent to plastic (BM-MSCs) was
used for subsequent experiments.
Transplantation of BM-MSCs
Twenty weeks after the induction of diabetes, we injected
BM-MSCs [1×10
6 cells/100 µL phosphate-buffer saline (PBS)
per limb] or the same volume of PBS into the hind limb
muscle percutaneously along the course of the sciatic nerve
at 4 sites using a 30-gauge needle [22]. Two and 4 weeks
later, the following parameters were measured.
Measurement of nerve conduction velocity
Mice were anesthetized with a combination of 100 mg/
kg ketamine and 10 mg/kg xylazine to prevent discomfort.
Body temperature was maintained at 37
oC using a warming
pad to ease animal stress from the anesthetic. The electrodes
were cleaned with 70% alcohol between animals to maintain
a pathogen-free status. The sciatic-tibial motor nerve
conduction velocity (MNCV) between the ankle and the sciatic
notch was determined with a recorder and bioamp (AD
Instruments, ML820 and ML132, Castle Hill, Australia). Briefly,
sciatic nerve was stimulated proximally at the sciatic notch
and distally at the ankle via electrodes previously inserted
through the skin with supramaximal stimulation (25 mA,
0.02 msec duration, AD Instruments, ML155). MNCV was
calculated by dividing the distance between stimulating
electrodes by the average latency difference between the
initial onset to maximum negative peaks of the compound
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Quantitative real-time polymerase-chain reaction
(PCR)
Tissue RNA samples were extracted from sciatic nerve and
femoral muscles of diabetic mice 2 and 4 weeks after
transplantation of STZ using RNeasy Lipid Tissue Mini kits
(Qiagen Korea, Seoul, Korea). The RNA concentration was
determined using a Nanodrop ND-1000 spectrophotometer.
Five µg of each RNA was converted to cDNA using the sprint
RT complete-oligo (dT) (Clontech, Palo Alto, CA, USA)
according to the manufacturer’s guide. The cDNA was
quantified using the QuantiTect SYBR Green PCR Kit (Qiagen
Korea). For each investigated transcript, a mixture of the
following reaction components was prepared at the indicated
end-concentrations: forward primer (10 pM), reverse primer
(10 pM) and QuantiTect SYBR Green PCR Master mix. The
15 µL master-mix was added to a 0.1 mL tube and 5 µL,
containing 100 ng reverse transcribed total RNA, was added
as a PCR template. The tubes were closed, centrifuged and
placed into a Corbett research RG-6000 real-time PCR
machine (Corbett Life Science, Sydney, Australia). The
following primers were used: NGF (forward: 5'-TCAGTGTG
TGGGTTGGAGAT-3', reverse: 5'-CCACTCTCAACAGGATT
GGA-3'), NT-3 (forward: 5'-TTCTGCCACGATCTTACAGG-3',
reverse: 5'-GGCAAACTCCTTTGATCCAT-3').
Statistical analysis
Data are expressed as mean±SEM. The independent t-
test was used to compare two groups. One-way ANOVA
was used to evaluate mean differences among experimental
groups. All data were analyzed using SPSS (PASW) win 18.0
version. P<0.05 was considered to be significant.
Results
BM-MSCs increased sciatic MNCV in STZ-treated
mice
To determine the impact of transplantation of BM-MSCs
on the sciatic nerve, we measured sciatic MNCV 12, 14
and 16 weeks after STZ treatment. At baseline, 12 weeks
after induction of diabetes, sciatic MNCV was significantly
Figure 1. Bone marrow-derived mesenchymal stem cells (BM-MSCs) transplantation improved sciatic motor nerve conduction
velocity (MNCV) in mice with diabetic neuropathy (DN). (A) 12 weeks after streptozotocin treatment, sciatic MNCV was significantly
delayed in streptozotocin-treated mice compared with normal mice (n=10 per group). After measurement of sciatic MNCV, BM-
MSCs were transplanted into the muscles percutaneously along the course of the sciatic nerve. (B) 2 weeks after BM-MSC
transplantation, a significant improvement of sciatic MNCV occurred in BM-MSCs injected diabetic mice (n=5 per group). (C) 4
weeks after BM-MSCs transplantation, there were no significant differences in sciatic MNCV between any of the diabetic mice
groups (n=5 per group). Data represent mean±SEM. Independent t-test, one-way ANOVA, *P<0.05 vs. normal mice; 
†P<0.05 vs.
diabetic mice treated with phosphate-buffered saline (PBS).174 Bae Jin Kim et al.
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delayed in STZ-treated mice compared with normal mice,
indicating development of diabetic neuropathy (Figure 1A).
STZ-treated mice were randomly assigned to BM-MSCs or
PBS injection groups and were injected intramuscularly around
the sciatic nerves. A significant improvement in sciatic MNCV
was observed in BM-MSC injected diabetic mice 2 weeks
after the injection (Figure 1B). However, 4 weeks after BM-
MSC injection, there were no significant differences in sciatic
MNCV among the diabetic mice (Figure 1C). These results
demonstrate that BM-MSCs improve peripheral nerve
conduction in STZ-treated mice. However, the effect of the
treatment lasts less than 4 weeks.
BM-MSCs increased expression levels of NTFs in
STZ-treated mice
Next, to determine whether nerve conduction increases
are associated with alterations in expression levels of NTFs,
such as NGF and NT-3, we performed quantitative real-time
PCR and examined their mRNA expression in sciatic nerve
and femoral muscles at 2 and 4 weeks after BM-MSCs
transplantation. Two weeks after transplantation, NGF and
NT-3 mRNA levels were significantly decreased in STZ-treated
diabetic mice compared with normal mice. The decrease
in mRNA expression in STZ-treated mice was ameliorated
by BM-MSCs transplantation (Figure 2A). Four weeks after
BM-MSCs transplantation, we found slightly increased NGF
and NT-3 mRNA levels in some groups, but these changes
were not statistically significant (Figure 2B). These results suggest
that BM-MSCs improve NTF function in STZ-treated mice.
However, in common with MNCV results, the effect of
treatment lasted less than 4 weeks.
Discussion
We measured sciatic MNCV 12 weeks after STZ treatment.
Sciatic MNCV was significantly decreased in STZ-treated mice
compared with normal mice (Figure 1A). In previous studies,
the decreased NGF and NT-3 content led to nerve dysfunction
of DN [23,24]. The delayed sciatic MNCV in PBS-injected
mice 14 weeks after STZ treatment was significantly
ameliorated by BM-MSCs transplantation (Figure 1B).To
determine whether the improvement in sciatic nerve
conduction is associated with alterations in expression levels
of NTFs, we examined NGF and NT-3 mRNA expression
Figure 2. Bone marrow-derived mesenchymal stem cells (BM-MSCs) transplantation increased expression levels of neurotrophic
factors (NTFs) in mice with diabetic neuropathy (DN). The mRNA expression levels of NTFs in sciatic nerve and muscle were
measured by quantitative real-time polymerase-chain reaction. (A) Two weeks after BM-MSCs transplantation, significant
improvement of expression levels of NTFs observed in the BM-MSCs injected diabetic mice (n=5 per group). (B) Four weeks after
BM-MSC transplantation, there was no significant difference in expression of NTFs between any of the diabetic mice groups (n=5
per group). Data represent mean±SEM. Independent t-test, one-way ANOVA, *P<0.05 vs. normal mice; 
†P<0.05 vs. diabetic mice
treated with phosphate-buffered saline (PBS).BM-MSCs improve neurotrophic functioning in diabetic neuropathy 175
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in sciatic nerve and femoral muscles. NGF and NT-3 mRNA
levels were significantly decreased in diabetic mice compared
with normal mice. The decrease in mRNA expression in
diabetic mice was ameliorated by BM-MSCs transplantation
(Figure 2A).
In the present study, local expression levels of NTFs were
decreased in DN mice. Impaired neurotrophic support plays
a crucial role in DN, and NTFs have been reported to have
a beneficial action on multiple manifestations of diabetes-
induced peripheral nerve injury [25]. For example, intrathecal
administration of NGF and NT-3 increased myelinated
innervation of the dermal footpad of diabetic mice, which
suggests that neurotrophic dysfunction plays a crucial role
in diabetes-induced impairment of myelinated cutaneous
innervations [26]. In the diabetic condition, NGF levels were
increased in sympathetic target tissues and decreased in sciatic
nerve and sympathetic ganglia [27]. It has been suggested
that axonal transport of NGF is impaired in diabetic conditions.
Interestingly, improved glucose control restores NGF levels,
suggesting that hyperglycemia may be responsible for these
abnormalities [28]. Decreased levels of NT-3 in diabetes might
contribute to the development of large-fiber sensory
neuropathy and later motor neuropathy [15]. Schwann cells
are essential for nerve regeneration and they synthesize NTFs
such as NGF, BDNF and NT-3, to provide trophic support
for regenerating axons [29,30]. Previous studies have
demonstrated that BM-MSCs have the capacity to
transdifferentiate into cells with a Schwann cell phenotype
[31,32]. However, functions of these transdifferentiated
Schwann cell-like cells are still questionable. Thus, we need
to consider the cellular pathways that mediate interactions
between BM-MSCs and Schwann cells.
Additionally, our data suggests that BM-MSCs ameliorated
various symptoms of experimental DN through effects on
peripheral nerves. However, this effect of the treatment lasts
less than 4 weeks. Recent observations indicate that only
small numbers of transplanted tissue-specific stem cells engraft
into most injured tissues, and they disappear quickly. For
example, when bone marrow specific stem cells were injected
into the hippocampus in immunodeficient mice, most
transplanted cells disappeared within 1 week [33]. Also, after
infusion of human MSCs into immunodeficient mice with
acute myocardial infarction, engrafted donor cells could not
be detected 3 weeks post-injection [34]. For the above reasons,
in our study, BM-MSCs might not be more effective on various
symptoms of DN at 4 weeks after transplantation.
In this study, we established that local transplantation of
BM-MSCs into the muscles around the sciatic nerve reversed
the impairment of sciatic MNCV and expression of NTFs
in DN mice. It is our hypothesis that reduced expression
of NTFs in nerves plays a crucial role in the development
and progression of DN, and therefore that therapeutic strategies
using BM-MSC transplantation can attenuate DN by supplying
NTFs. The present results are the first report that NGF and
NT-3 up-regulation in DN are mutually mediated with BM-
MSCs. Thus, these results help to elucidate the mechanism
by which BM-MSCs function as a cell therapy agent in diabetic
neuropathy.
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